A further bispecific, humanized IgG1 antibody that's underneath investigation is zenocutuzumab (MCLA-128), which acts via two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 functions by means of a ‘dock and block’ system whereby a single arm of your antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/